80 research outputs found

    Simple models of the chemical field around swimming plankton

    Get PDF
    Background. Cervical cancer is the fourth most common cancer in women, and we recently reported human leukocyte antigen (HLA) alleles showing strong associations with cervical neoplasia risk and protection. HLA ligands are recognized by killer immunoglobulin-like receptors (KIRs) expressed on a range of immune cell subsets, governing their proinflammatory activity. We hypothesized that the inheritance of particular HLA-KIR combinations would increase cervical neoplasia risk. Methods. Here, we used HLA and KIR dosages imputed from single-nucleotide polymorphism genotype data from 2143 cervical neoplasia cases and 13 858 healthy controls of European decent. Results. The following 4 novel HLA alleles were identified in association with cervical neoplasia, owing to their linkage disequilibrium with known cervical neoplasia-associated HLA-DRB1 alleles: HLA-DRB3*9901 (odds ratio [OR], 1.24; P = 2.49 × 10−9), HLA-DRB5*0101 (OR, 1.29; P = 2.26 × 10−8), HLA-DRB5*9901 (OR, 0.77; P = 1.90 × 10−9), and HLA-DRB3*0301 (OR, 0.63; P = 4.06 × 10−5). We also found that homozygosity of HLA-C1 group alleles is a protective factor for human papillomavirus type 16 (HPV16)-related cervical neoplasia (C1/C1; OR, 0.79; P = .005). This protective association was restricted to carriers of either KIR2DL2 (OR, 0.67; P = .00045) or KIR2DS2 (OR, 0.69; P = .0006). Conclusions. Our findings suggest that HLA-C1 group alleles play a role in protecting against HPV16-related cervical neoplasia, mainly through a KIR-mediated mechanism

    Development of Metarhizium anisopliae and Beauveria bassiana formulations for control of malaria mosquito larvae

    Get PDF
    <p>Abstract</p> <p>Background</p> <p>The entomopathogenic fungi <it>Metarhizium anisopliae </it>and <it>Beauveria bassiana </it>have demonstrated effectiveness against anopheline larvae in the laboratory. However, utilising these fungi for the control of anopheline larvae under field conditions, relies on development of effective means of application as well as reducing their sensitivity to UV radiation, high temperatures and the inevitable contact with water. This study was conducted to develop formulations that facilitate the application of <it>Metarhizium anisopliae </it>and <it>Beauveria bassiana </it>spores for the control of anopheline larvae, and also improve their persistence under field conditions.</p> <p>Methods</p> <p>Laboratory bioassays were conducted to test the ability of aqueous (0.1% Tween 80), dry (organic and inorganic) and oil (mineral and synthetic) formulations to facilitate the spread of fungal spores over the water surface and improve the efficacy of formulated spores against anopheline larvae as well as improve spore survival after application. Field bioassays were then carried out to test the efficacy of the most promising formulation under field conditions in western Kenya.</p> <p>Results</p> <p>When formulated in a synthetic oil (ShellSol T), fungal spores of both <it>Metarhizium anisopliae </it>and <it>Beauveria bassiana </it>were easy to mix and apply to the water surface. This formulation was more effective against anopheline larvae than 0.1% Tween 80, dry powders or mineral oil formulations. ShellSol T also improved the persistence of fungal spores after application to the water. Under field conditions in Kenya, the percentage pupation of <it>An. gambiae </it>was significantly reduced by 39 - 50% by the ShellSol T-formulated <it>Metarhizium anisopliae </it>and <it>Beauveria bassiana </it>spores as compared to the effects of the application of unformulated spores.</p> <p>Conclusions</p> <p>ShellSol T is an effective carrier for fungal spores when targeting anopheline larvae under both laboratory and field conditions. Entomopathogenic fungi formulated with a suitable carrier are a promising tool for control of larval populations of malaria mosquitoes. Additional studies are required to identify the best delivery method (where, when and how) to make use of the entomopathogenic potential of these fungi against anopheline larvae.</p

    Protocol for a randomised controlled trial of treatment of asymptomatic candidiasis for the prevention of preterm birth [ACTRN12610000607077]

    Get PDF
    <p>Abstract</p> <p>Background</p> <p>Prevention of preterm birth remains one of the most important challenges in maternity care. We propose a randomised trial with: a simple <it>Candida </it>testing protocol that can be easily incorporated into usual antenatal care; a simple, well accepted, treatment intervention; and assessment of outcomes from validated, routinely-collected, computerised databases.</p> <p>Methods/Design</p> <p>Using a prospective, randomised, open-label, blinded-endpoint (PROBE) study design, we aim to evaluate whether treating women with asymptomatic vaginal candidiasis early in pregnancy is effective in preventing spontaneous preterm birth. Pregnant women presenting for antenatal care <20 weeks gestation with singleton pregnancies are eligible for inclusion. The intervention is a 6-day course of clotrimazole vaginal pessaries (100 mg) and the primary outcome is spontaneous preterm birth <37 weeks gestation.</p> <p>The study protocol draws on the usual antenatal care schedule, has been pilot-tested and the intervention involves only a minor modification of current practice. Women who agree to participate will self-collect a vaginal swab and those who are culture positive for Candida will be randomised (central, telephone) to open-label treatment or usual care (screening result is not revealed, no treatment, routine antenatal care). Outcomes will be obtained from population databases.</p> <p>A sample size of 3,208 women with <it>Candida </it>colonisation (1,604 per arm) is required to detect a 40% reduction in the spontaneous preterm birth rate among women with asymptomatic candidiasis from 5.0% in the control group to 3.0% in women treated with clotrimazole (significance 0.05, power 0.8). Analyses will be by intention to treat.</p> <p>Discussion</p> <p>For our hypothesis, a placebo-controlled trial had major disadvantages: a placebo arm would not represent current clinical practice; knowledge of vaginal colonisation with <it>Candida </it>may change participants' behaviour; and a placebo with an alcohol preservative may have an independent affect on vaginal flora. These disadvantages can be overcome by the PROBE study design.</p> <p>This trial will provide definitive evidence on whether screening for and treating asymptomatic candidiasis in pregnancy significantly reduces the rate of spontaneous preterm birth. If it can be demonstrated that treating asymptomatic candidiasis reduces preterm births this will change current practice and would directly impact the management of every pregnant woman.</p> <p>Trial registration</p> <p>Australian New Zealand Clinical Trials Registry <a href="http://www.anzctr.org.au/ACTRN12610000607077.aspx">ACTRN12610000607077</a></p

    Spectrin-based skeleton as an actor in cell signaling

    Get PDF
    This review focuses on the recent advances in functions of spectrins in non-erythroid cells. We discuss new data concerning the commonly known role of the spectrin-based skeleton in control of membrane organization, stability and shape, and tethering protein mosaics to the cellular motors and to all major filament systems. Particular effort has been undertaken to highlight recent advances linking spectrin to cell signaling phenomena and its participation in signal transduction pathways in many cell types

    Thousands of Rab GTPases for the Cell Biologist

    Get PDF
    Rab proteins are small GTPases that act as essential regulators of vesicular trafficking. 44 subfamilies are known in humans, performing specific sets of functions at distinct subcellular localisations and tissues. Rab function is conserved even amongst distant orthologs. Hence, the annotation of Rabs yields functional predictions about the cell biology of trafficking. So far, annotating Rabs has been a laborious manual task not feasible for current and future genomic output of deep sequencing technologies. We developed, validated and benchmarked the Rabifier, an automated bioinformatic pipeline for the identification and classification of Rabs, which achieves up to 90% classification accuracy. We cataloged roughly 8.000 Rabs from 247 genomes covering the entire eukaryotic tree. The full Rab database and a web tool implementing the pipeline are publicly available at www.RabDB.org. For the first time, we describe and analyse the evolution of Rabs in a dataset covering the whole eukaryotic phylogeny. We found a highly dynamic family undergoing frequent taxon-specific expansions and losses. We dated the origin of human subfamilies using phylogenetic profiling, which enlarged the Rab repertoire of the Last Eukaryotic Common Ancestor with Rab14, 32 and RabL4. Furthermore, a detailed analysis of the Choanoflagellate Monosiga brevicollis Rab family pinpointed the changes that accompanied the emergence of Metazoan multicellularity, mainly an important expansion and specialisation of the secretory pathway. Lastly, we experimentally establish tissue specificity in expression of mouse Rabs and show that neo-functionalisation best explains the emergence of new human Rab subfamilies. With the Rabifier and RabDB, we provide tools that easily allows non-bioinformaticians to integrate thousands of Rabs in their analyses. RabDB is designed to enable the cell biology community to keep pace with the increasing number of fully-sequenced genomes and change the scale at which we perform comparative analysis in cell biology

    Đ­ĐșŃĐżĐ”Ń€ĐžĐŒĐ”ĐœŃ‚Đ°Đ»ŃŒĐœĐŸĐ” ĐžĐ·ŃƒŃ‡Đ”ĐœĐžĐ” ĐČĐ»ĐžŃĐœĐžŃ глюĐșĐŸĐ·Đ°ĐŒĐžĐœĐ° ĐłĐžĐŽŃ€ĐŸŃ…Đ»ĐŸŃ€ĐžĐŽĐ° ĐœĐ° разĐČОтОД ĐżĐ°Ń‚ĐŸŃĐżĐ”Ń€ĐŒĐžĐž старДющОх Đșрыс, ĐČŃ‹Đ·ĐČĐ°ĐœĐœĐŸĐč ĐŽĐŸĐșŃĐŸŃ€ŃƒĐ±ĐžŃ†ĐžĐœĐŸĐŒ

    Get PDF
    ГЛмКОЗАМИНА Đ“Đ˜Đ”Đ ĐžĐ„Đ›ĐžĐ Đ˜Đ”Đ”ĐžĐšĐĄĐžĐ ĐŁĐ‘Đ˜ĐŠĐ˜ĐĐŸĐĐąĐžĐĄĐŸĐ•Đ ĐœĐ˜ĐŻĐĄĐąĐĐ Đ•ĐĐ˜Đ•Đ€ĐĐ ĐœĐĐšĐžĐ›ĐžĐ“Đ˜ĐŻ КЛИНИЧЕСКАЯЛЕКАРСбВ Đ€Đ˜Đ—Đ˜ĐžĐ›ĐžĐ“Đ˜Đ§Đ•ĐĄĐšĐžĐ• ДЕЙСбВИЕРЕПРОДУКЩИм ĐšĐžĐĐąĐ ĐžĐ›Đ˜Đ ĐŁĐźĐ©Đ˜Đ• ĐĄĐ Đ•Đ”ĐĄĐąĐ’ĐĐ­ĐšĐĄĐŸĐ•Đ Đ˜ĐœĐ•ĐĐąĐ« НА Đ–Đ˜Đ’ĐžĐąĐĐ«Đ„ĐšĐ Đ«ĐĄĐ«ĐŠĐ”Đ»ŃŒ Ń€Đ°Đ±ĐŸŃ‚Ń‹ - ĐžŃŃĐ»Đ”ĐŽĐŸĐČĐ°ĐœĐžĐ” ĐČĐ»ĐžŃĐœĐžŃ глюĐșĐŸĐ·Đ°ĐŒĐžĐœĐ° ĐłĐžĐŽŃ€ĐŸŃ…Đ»ĐŸŃ€ĐžĐŽĐ° ĐœĐ° разĐČОтОД ĐłĐžĐżĐŸŃ„ŃƒĐœĐșцоо ŃĐ”ĐŒĐ”ĐœĐœĐžĐșĐŸĐČ Đșрыс, ĐČŃ‹Đ·ĐČĐ°ĐœĐœĐŸĐč ĐŽĐ»ĐžŃ‚Đ”Đ»ŃŒĐœŃ‹ĐŒ ĐČĐČĐ”ĐŽĐ”ĐœĐžĐ”ĐŒ ĐŽĐŸĐșŃĐŸŃ€ŃƒĐ±ĐžŃ†ĐžĐœĐ° ĐœĐ° Ń„ĐŸĐœĐ” ŃŃ‚Đ°Ń€Đ”ĐœĐžŃ жОĐČĐŸŃ‚ĐœŃ‹Ń…

    The V471A polymorphism in autophagy-related gene ATG7 modifies age at onset specifically in Italian Huntington disease patients

    Get PDF
    The cause of Huntington disease (HD) is a polyglutamine repeat expansion of more than 36 units in the huntingtin protein, which is inversely correlated with the age at onset of the disease. However, additional genetic factors are believed to modify the course and the age at onset of HD. Recently, we identified the V471A polymorphism in the autophagy-related gene ATG7, a key component of the autophagy pathway that plays an important role in HD pathogenesis, to be associated with the age at onset in a large group of European Huntington disease patients. To confirm this association in a second independent patient cohort, we analysed the ATG7 V471A polymorphism in additional 1,464 European HD patients of the “REGISTRY” cohort from the European Huntington Disease Network (EHDN). In the entire REGISTRY cohort we could not confirm a modifying effect of the ATG7 V471A polymorphism. However, analysing a modifying effect of ATG7 in these REGISTRY patients and in patients of our previous HD cohort according to their ethnic origin, we identified a significant effect of the ATG7 V471A polymorphism on the HD age at onset only in the Italian population (327 patients). In these Italian patients, the polymorphism is associated with a 6-years earlier disease onset and thus seems to have an aggravating effect. We could specify the role of ATG7 as a genetic modifier for HD particularly in the Italian population. This result affirms the modifying influence of the autophagic pathway on the course of HD, but also suggests population-specific modifying mechanisms in HD pathogenesis

    International Consensus Statement on Rhinology and Allergy: Rhinosinusitis

    Get PDF
    Background: The 5 years since the publication of the first International Consensus Statement on Allergy and Rhinology: Rhinosinusitis (ICAR‐RS) has witnessed foundational progress in our understanding and treatment of rhinologic disease. These advances are reflected within the more than 40 new topics covered within the ICAR‐RS‐2021 as well as updates to the original 140 topics. This executive summary consolidates the evidence‐based findings of the document. Methods: ICAR‐RS presents over 180 topics in the forms of evidence‐based reviews with recommendations (EBRRs), evidence‐based reviews, and literature reviews. The highest grade structured recommendations of the EBRR sections are summarized in this executive summary. Results: ICAR‐RS‐2021 covers 22 topics regarding the medical management of RS, which are grade A/B and are presented in the executive summary. Additionally, 4 topics regarding the surgical management of RS are grade A/B and are presented in the executive summary. Finally, a comprehensive evidence‐based management algorithm is provided. Conclusion: This ICAR‐RS‐2021 executive summary provides a compilation of the evidence‐based recommendations for medical and surgical treatment of the most common forms of RS
    • 

    corecore